Toggle light / dark theme

How antibody therapy clears Alzheimer’s plaques: Key immune mechanism identified

Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer’s disease that clears toxic amyloid plaques and delays cognitive decline. Researchers from VIB and KU Leuven have now demonstrated the mechanism behind it for the first time.

They showed that the “Fc fragment” of this monoclonal antibody is essential for engaging microglia—the immune cells of the brain—thus initiating the cellular machinery needed for plaque removal. This is the first direct mechanistic explanation for how this class of therapies works. It clarifies uncertainties in the field and offers a blueprint for developing safer, more effective Alzheimer’s treatments. The findings are published in Nature Neuroscience.

“Our study is the first to clearly demonstrate how this anti-amyloid antibody therapy works in Alzheimer’s disease. We show that the therapy’s efficacy relies on the antibody’s Fc fragment, which activates microglia to effectively clear amyloid plaques,” says Dr. Giulia Albertini, co-first author of the study. “The Fc fragment works as an anchor that microglia latch onto when they are near plaques, as a consequence of which these cells are reprogrammed to clear plaques more efficiently.”

Reducing social media use for just a week can improve mental health

In a new study, published in JAMA Network Open, 295 participants report promising mental health benefits after reducing their social media usage for a week. The cohort consisted of young adults from the ages of 18 to 24—the age group commonly associated with the highest social media usage, as well as a heightened risk of mental health issues.

Although many self-reports have surfaced online indicating that reducing social media use has been beneficial in various ways, the scientific link between social media use and youth mental health is still debated, with past studies showing mixed results.

Study reveals unexpected link between dopamine and serotonin in the brain

Researchers at Karolinska Institutet, Columbia University and the University of San Francisco, have uncovered a previously unknown mechanism by which dopamine, a key brain chemical vital for movement and motivation, can affect brain activity indirectly by boosting serotonin. The study was published in Science Advances.

Dopamine is a key chemical messenger that supports many essential brain functions, including motivation, movement, and learning. Although dopamine acts throughout the brain, it plays an especially central role in the basal ganglia, a network of interconnected regions responsible for selecting which behaviors we express.

The basal ganglia and dopamine are deeply involved in neuropsychiatric and neurodegenerative diseases, and many widely used medications target this network.

Collaborating minds think alike, processing information in similar ways in a shared task, study shows

Whether great minds think alike is up for debate, but the collaborating minds of two people working on a shared task process information alike, according to a study published in PLOS Biology by Denise Moerel and colleagues from Western Sydney University in Australia.

Humans rely on collaboration for everything from raising food to raising children. But to cooperate successfully, people need to make sure that they are seeing the same things and working within the same rules. We must agree that the red fruits are the ones that are ripe and that we will leave green fruits alone.

Behavioral collaboration requires that people think in the same way and follow the same instructions. To better understand people’s cognitive processes during a shared task, the authors of this study collected data from 24 pairs of people.